Tag: Luye Pharma
Positive results for Luye Pharma schizophrenia drug
Luye Pharma’s pipeline asset LY03010, a once-monthly, long-acting injectable (LAI) form of paliperidone, has achieved the primary endpoint in a pivotal trial and demonstrated...